Scientists at the Sungkyunkwan University School of Medicine have found a genetic variation that influences how patients respond to different classes of antidepressants.
Of 241 male and female Korean patients with major late-life depression, 136 were treated with selective serotonin reuptake inhibitors (SSRIs) for six weeks while the remaining 105 received norepinephrine reuptake inhibitors (NRIs). They were also screened for variations in the genes affecting the transport of serotonin, norepinephrine, and dopamine
Researchers found that for individuals possessing the GG variation of a gene known as NET G1287A, NRIs had an 88.3 percent success rate in comparison with just 58.7 percent for SSRIs. Individuals with other variations meanwhile, showed better response to SSRIs such as fluoxetine (Prozac).
Researchers hope further investigation will help fine-tune initial prescription based on the genetic makeup of an individual.
Add to:
Digg
del.icio.us
del.icio.us |
digg |
FURL |
Netscape |
reddit |
Stumble! |
My Web
